| Submit your comments on this article |
| -Land of the Free |
| Government Control Led to Lack of Monoclonal Antibodies, Says Medical Supplies CEO |
| 2022-01-15 |
| [THEEPOCHTIMES] The head of a medical supplies company involved in the distribution and supply of monoclonal antibodies across southeastern and northeastern regions of the nation, told NTD in a Jan. 12 interview that government takeover of the monoclonal antibody supply chain has exacerbated backlogs and shortages."The way the products are being distributed right now, relying on the government to determine who gets what, that process can be very lengthy in terms of time," Dealmed CEO Michael Einhorn said. As a result, physicians are reporting "surpluses in certain areas, not enough in other areas" which has fueled frustrations when critical patients are not receiving antibodies for COVID-19 infections. While it’s unclear how the monoclonal antibodies are being rationed among states, Einhorn said that "commercialization" of these products should be allowed, so that infusion centers that need them can order in products based on "patient volume." "If they have oversupply they wouldn’t order more," Einhorn said, whereas when remedies are supplied by the state, "nobody’s going to say no the government" as the products are "free practically," leading to mismatches in supply and demand. "I find it very difficult to believe that, in a mere year, a governmental agency in a different state can figure out the dynamics of a local regional health care system," he added. One particular monoclonal antibody, sotrovimab made by GlaxoSmithKline (GSK) and Vir Biotechnology, is in high demand as emerging reports suggest it is more effective than other products against Omicron. Dr. Marc Siegel, a practicing internist and a professor of medicine at NYU’s Langone Medical Center, wrote in an op-ed in USA Today that "Omicron is most susceptible to sotrovimab, made by GlaxoSmithKline, but in most states, it is almost impossible to find." Monoclonal antibody therapies have been shown to be effective in preventing severe disease or hospitalization in high-risk patients with mild to moderate COVID-19. |
| Posted by:Fred |
| #4 Yet Hunter still has all the crack he can smoke. |
| Posted by: Woodrow 2022-01-15 21:53 |
| #3 AFAICT, the feds bought and paid for all the Mabs available to treat COVID-19. There may be a few exceptions (FL was said to have purchased some of their own). No statistics are available showing the numbers of patients eligible to receive MAbs under the FDA EUA protocols, but almost certainly the number of eligible patients far exceeds the number of doses to match. Of course there will be a relative "lack" of Mabs no matter how they are distributed, and they do have to be distributed IN ADVANCE OF NEED. That's called a "supply chain". It doesn't help matters that the feds are secretly deciding where to send the stuff, and the public is increasingly distrusting all fed efforts. The same issue is going on with the 2 newly EUA's oral anti COVID meds. The number of eligible recipients as of today would almost certainly exhaust the entire available supply of meds, even if the patients could figure out which pharmacies and hospital systems have them in stock. |
| Posted by: Bubba Lover of the Faeries8843 2022-01-15 17:49 |
| #2 "If you put the federal government in charge of the Sahara Desert, in five years there’d be a shortage of sand." The government has gotten more efficient at inefficiency. It's down to two years now. |
| Posted by: Warthog 2022-01-15 07:31 |
| #1 But you can get fentanyl pretty much everywhere, hey what. That's probably part of the plan too. |
| Posted by: M. Murcek 2022-01-15 00:45 |